Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Zawarcie umowy z Pharmalink w zakresie komercjalizacji leku Reduzek (semaglutyd) w wybranych krajach Zatoki Perskiej - Content (EN)
Regulatory Filings Classification · 80% confidence The document is a regulatory disclosure under Article 17(1) of the Market Abuse Regulation (MAR), announcing the execution of a license and supply agreement for commercialization (inside information). It is not a full financial report, earnings release, or M&A deal, but rather a mandatory regulatory announcement. Therefore it is classified as a general regulatory filing (RNS).
2026-06-08 English
Zawarcie umowy z Pharmalink w zakresie komercjalizacji leku Reduzek (semaglutyd) w wybranych krajach Zatoki Perskiej - Content (PL)
Regulatory Filings Classification · 72% confidence The document is a corporate announcement describing the terms of a new license and supply agreement for the company’s semaglutide products. It does not present financial statements (so not a report), nor does it involve share issuance, dividends, management changes, M&A bids, or other specialised categories. It is therefore best classified under the fallback category for miscellaneous regulatory announcements.
2026-06-08 Polish
Przydział warrantów subskrypcyjnych serii A osobom uprawnionym w ramach Programu Motywacyjnego dla kadry kierowniczej - Content (PL)
Share Issue/Capital Change Classification · 91% confidence The document is a regulatory “current report” in which the Board of Celon Pharma S.A. announces the allocation of 55,000 subscription warrants and the related conditional capital increase under its incentive program. This constitutes an announcement of a new issuance of equity-linked instruments (capital change). Under our taxonomy, this falls squarely into the “Share Issue/Capital Change” category (SHA).
2026-06-03 Polish
Raport z oceny SoW 2025
Audit Report / Information Classification · 95% confidence The document is an independent auditor’s (PwC) attestation report providing an opinion on the completeness and compliance of the Company’s Remuneration Report (“Sprawozdanie o wynagrodzeniach”) for the year ended December 31, 2025. It contains auditor responsibilities, applicable standards (KSUA 3000 (Z)), scope of work, and an audit opinion. This is a standalone audit/attestation report rather than a full annual or interim financial statement, and thus it fits the Audit Report / Information category. FY 2025
2026-05-28 Polish
Sprawozdanie o wynagrodzeniach 2025
Remuneration Information Classification · 95% confidence The document is a detailed ‘sprawozdanie o wynagrodzeniach’ (remuneration report) for members of the Management Board (Zarząd) and Supervisory Board (Rada Nadzorcza) of Celon Pharma S.A. for the 2025 period. It outlines compensation policies, fixed and variable pay, benefits, and compliance with the remuneration policy. This matches the definition of a standalone Remuneration Information filing (Code: DEF 14A).
2026-05-28 Polish
Sprawozdanie RN 2025
Governance Information Classification · 90% confidence The document is titled “Sprawozdanie Rady Nadzorczej” (Supervisory Board Report) of Celon Pharma S.A. for the 2025 fiscal year and includes detailed governance-related content: composition of the Supervisory Board, committees, evaluation of the financial statements, internal controls, compliance with corporate governance practices, and recommendations to the General Meeting. It is not the full Annual Report (no comprehensive management discussion & analysis with complete financial exhibits), nor an earnings release or proxy statement, nor an audit report per se. It is a governance report outlining board structure and oversight activities, which corresponds to the Governance Information category (CGR).
2026-05-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.